If you are not happy with the results below please do another search
Antibodies against the novel coronavirus declined rapidly in the British population during the summer, a study found, suggesting protection after infection may not be long lasting and raising the prospect of waning immunity in the community.
In a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, a new study may help identify which Covid-19 patients with signs of heart injury are at higher risk for death.
The number of new Covid-19 cases in the United States last week rose 24% to more than 485,000 while the number of tests performed rose 5.5%, according to a Reuters analysis of state and county reports.
FibroGen Provides More Support for Roxadustat in Anemia Associated with Kidney Disease Published: Oct. 26, 2020 By Mark Terry BioSpace FibroGen presented data from two pooled analyses from its roxadustat global Phase III development program this weekend at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined conference. The analyses looked at associations between the […]
Days after the U.S. Food and Drug Administration greenlit the restart of AstraZeneca’s Phase III Covid-19 vaccine trial, the U.K.-based company said the preventative medication boosts immune responses in older and younger adults against the novel coronavirus.
Novartis released promising interim Phase II data of iptacopan in C3 glomerulopathy (C3G) at the virtual American Society of Nephrology 2020 Annual Meeting.
Spectrum Pharmaceuticals announced that an inspection of the Hanmi Bioplant in South Korea will be necessary before the U.S. Food and Drug Administration can approve the company’s Biologics License Application for Rolontis (eflapegrastim).
Bayer is making a big bet on gene therapy with the acquisition of North Carolina-based Asklepios BioPharmaceutical (AskBio).
The United States, Russia and France set new daily records for coronavirus infections as a second wave swelled across parts of the Northern Hemisphere, forcing some countries to impose new curbs.
South Korea’s Celltrion Inc. received emergency use authorization (EUA) from the U.S. Food and Drug Administration for the rapid Covid-19 testing kit Sampinute, which boosted shares of the company and its affiliates.